Dre Angela Orcurto

Médecin cadre hospitalière
Service d'immuno-oncologie
Département d'oncologie UNIL CHUV

Contacter par mail
+41 21 314 60 39

Specialisations

Urologie, immuno-oncologie

Domaines d'intérêt académique et/ou clinique

Cancers urologiques, mélanome et immuno-oncologie

Publications scientifiques sélectionnées

2022

[2021 Oncology update].

Meyer ML, Chrysou K, Stamatiou A, Gilabert M, Herrera Gomez RG, Latifyan S, Masmoudi S, Mederos N, Perrinjaquet C, Berthold D, Bouchaab H, Cristina V, Digklia A, Michielin O, Orcurto A, Sarivalasis A, Stravodimou A, Wagner AD, Zaman K, Peters S, Jankovic

Rev Med Suisse. 2022 Feb 2;18(767):182-186

Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.

Herrera FG, Ronet C, Ochoa de Olza M, Barras D, Crespo I, Andreatta M, Corria-Osorio J, Spill A, Benedetti F, Genolet R, Orcurto A, Imbimbo M, Ghisoni E, Navarro Rodrigo B, Berthold DR, Sarivalasis A, Zaman K, Duran R, Dromain C, Prior J, Schaefer N, Bour

Cancer Discov. 2022 Jan;12(1):108-133

2021

A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma.

Harari A, Sarivalasis A, de Jonge K, Thierry AC, Huber F, Boudousquie C, Rossier L, Orcurto A, Imbimbo M, Baumgaertner P, Bassani-Sternberg M, Kandalaft LE

Cancers (Basel). 2021 Nov 18;13(22)

Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data.

Bandiera C, Cardoso E, Locatelli I, Digklia A, Zaman K, Diciolla A, Cristina V, Stravodimou A, Veronica AL, Dolcan A, Sarivalasis A, Liapi A, Bouchaab H, Orcurto A, Dotta-Celio J, Peters S, Decosterd L, Widmer N, Wagner D, Csajka C, Schneider MP

JMIR Res Protoc. 2021 Jun 29;10(6):e30090

[Immunotherapy for bladder cancer in 2021].

Cisarovsky C, Latifyan S, Perrinjaquet C, Berthold D, Orcurto A

Rev Med Suisse. 2021 May 19;17(739):974-977

2020

Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes.

Orcurto A, Hottinger A, Wolf B, Navarro Rodrigo B, Ochoa de Olza M, Auger A, Kuntzer T, Comte D, Zimmer V, Gannon P, Kandalaft L, Michielin O, Zimmermann S, Harari A, Trueb L, Coukos G

J Immunother Cancer. 2020 Aug;8(2)

Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review.

Colomer-Lahiguera S, Bryant-Lukosius D, Rietkoetter S, Martelli L, Ribi K, Fitzpatrick-Lewis D, Sherifali D, Orcurto A, Juergens R, Eicher M

J Patient Rep Outcomes. 2020 Jul 16;4(1):58

2019

Efficacy of Adoptive Therapy with Tumor-infiltrating Lymphocytes and Recombinant Interleukin-2 in Advanced Cutaneous Melanoma: A Systematic Review and Meta-analysis.

Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, Besser MJ, Haanen J, Svane IM, Ohashi PS, Kammula US, Orcurto A, Zimmermann S, Trueb L, Klebanoff CA, Lotze MT, Kandalaft LE, Coukos G

Ann Oncol. 2019 Sep 30